It remains to be seen whether the performance of biopharmaceutical company initial public offerings in the US this year will cause investors to rethink their strategies but returns from IPOs so far this month could test IPO backers’ patience.
The eight companies that have gone public so far in July have delivered an average loss of -7% (see table below)
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?